Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 24550334)

1.

Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration.

W S Yapa S, Li J, Patel K, Wilson JW, Dooley MJ, George J, Clark D, Poole S, Williams E, Porter CJ, Nation RL, McIntosh MP.

Antimicrob Agents Chemother. 2014 May;58(5):2570-9. doi: 10.1128/AAC.01705-13. Epub 2014 Feb 18.

2.

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H.

J Antimicrob Chemother. 2006 Feb;57(2):306-11. Epub 2006 Jan 5.

3.

Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients.

Boisson M, Jacobs M, Grégoire N, Gobin P, Marchand S, Couet W, Mimoz O.

Antimicrob Agents Chemother. 2014 Dec;58(12):7331-9. doi: 10.1128/AAC.03510-14. Epub 2014 Sep 29.

4.

Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections.

W S Yapa S, Li J, Porter CJ, Nation RL, Patel K, McIntosh MP.

Antimicrob Agents Chemother. 2013 Oct;57(10):5087-95. doi: 10.1128/AAC.01127-13. Epub 2013 Aug 5.

5.

Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J.

J Antimicrob Chemother. 2003 Dec;52(6):987-92. Epub 2003 Oct 29.

6.

Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients.

Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ.

Intensive Care Med. 2012 Nov;38(11):1779-86. doi: 10.1007/s00134-012-2628-7. Epub 2012 Jul 19.

PMID:
22810779
7.

Systemic absorption of nasally administered tobramycin and colistin in patients with cystic fibrosis.

Berkhout MC, van Velzen AJ, Touw DJ, de Kok BM, Fokkens WJ, Heijerman HG.

J Antimicrob Chemother. 2014 Nov;69(11):3112-5. doi: 10.1093/jac/dku239. Epub 2014 Jul 11.

PMID:
25016384
8.

Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses.

Marchand S, Lamarche I, Gobin P, Couet W.

J Antimicrob Chemother. 2010 Aug;65(8):1753-8. doi: 10.1093/jac/dkq183. Epub 2010 May 27.

9.

Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K.

J Antimicrob Chemother. 2004 May;53(5):837-40. Epub 2004 Mar 24.

10.

New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale.

Grégoire N, Mimoz O, Mégarbane B, Comets E, Chatelier D, Lasocki S, Gauzit R, Balayn D, Gobin P, Marchand S, Couet W.

Antimicrob Agents Chemother. 2014 Dec;58(12):7324-30. doi: 10.1128/AAC.03508-14. Epub 2014 Sep 29.

11.

Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects.

Mizuyachi K, Hara K, Wakamatsu A, Nohda S, Hirama T.

Curr Med Res Opin. 2011 Dec;27(12):2261-70. doi: 10.1185/03007995.2011.626557. Epub 2011 Oct 14. Erratum in: Curr Med Res Opin. 2015 Mar;31(3):593-4. 2015 Mar;31(3):593-4. Dosage error in article text..

PMID:
21995648
12.

Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria.

Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H.

Antimicrob Agents Chemother. 2009 Aug;53(8):3430-6. doi: 10.1128/AAC.01361-08. Epub 2009 May 11.

13.

Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.

Stass H, Weimann B, Nagelschmitz J, Rolinck-Werninghaus C, Staab D.

Clin Ther. 2013 Oct;35(10):1571-81. doi: 10.1016/j.clinthera.2013.08.003. Epub 2013 Sep 18.

14.

Pharmacokinetics of colistin methanesulfonate and formed colistin in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis.

Koomanachai P, Landersdorfer CB, Chen G, Lee HJ, Jitmuang A, Wasuwattakul S, Sritippayawan S, Li J, Nation RL, Thamlikitkul V.

Antimicrob Agents Chemother. 2014;58(1):440-6. doi: 10.1128/AAC.01741-13. Epub 2013 Nov 4.

15.
16.

Comment on: pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

Li J, Nation RL.

J Antimicrob Chemother. 2006 Jul;58(1):222-3; author reply 223. Epub 2006 Apr 26. No abstract available.

17.

Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats.

Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W.

Antimicrob Agents Chemother. 2010 Sep;54(9):3702-7. doi: 10.1128/AAC.00411-10. Epub 2010 Jun 14.

18.

Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study.

Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG.

J Cyst Fibros. 2007 Jul;6(4):284-92. Epub 2006 Dec 20.

19.

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

Le Brun PP, de Boer AH, Mannes GP, de Fraîture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG.

Eur J Pharm Biopharm. 2002 Jul;54(1):25-32.

PMID:
12084499
20.

Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill.

Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE.

Antimicrob Agents Chemother. 2012 Aug;56(8):4241-9. doi: 10.1128/AAC.06426-11. Epub 2012 May 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk